Feedback / Questions
sifalimumab (MDX-1103) - AstraZeneca
AstraZeneca: Investor Relations Presentation
(AstraZeneca)
-
Mar 21, 2015 -
"Sifalimumab (lupus): Significant improvement in SLE responder index and organ specific measurements specific measurements"
P2 data
•
Immunology • Lupus
http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&blobheader=application%2Fpdf&blobheadername1=Content-Disposition&blobheadername2=MDT-Type&blobheadervalue1=inline%3B+filename%3DInvestor-Relations-presentation.pdf&blobheadervalue2=abinary%3B+charset%3DUTF-8&blobkey=id&blobtable=MungoBlobs&blobwhere=1285689187727&ssbinary=true
Mar 21, 2015
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
.